These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 36304684)

  • 21. Comparative safety and effectiveness of direct oral anticoagulants in patients with atrial fibrillation in clinical practice in Scotland.
    Mueller T; Alvarez-Madrazo S; Robertson C; Wu O; Bennie M
    Br J Clin Pharmacol; 2019 Feb; 85(2):422-431. PubMed ID: 30423191
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Determinants for under- and overdosing of direct oral anticoagulants and physicians' implementation of clinical pharmacists' recommendations.
    Moudallel S; Cornu P; Dupont A; Steurbaut S
    Br J Clin Pharmacol; 2022 Feb; 88(2):753-763. PubMed ID: 34331720
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quality of direct oral anticoagulant prescribing in elderly patients with non-valvular atrial fibrillation: results from a large urban health system.
    Grant SJ; Kothari S; Gimotty PA; Gooneratne NS; Cuker A
    J Thromb Thrombolysis; 2018 Jul; 46(1):1-6. PubMed ID: 29611105
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population.
    Amin A; Keshishian A; Trocio J; Dina O; Le H; Rosenblatt L; Liu X; Mardekian J; Zhang Q; Baser O; Vo L
    Curr Med Res Opin; 2017 Sep; 33(9):1595-1604. PubMed ID: 28635338
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dose specific effectiveness and safety of DOACs in patients with non-valvular atrial fibrillation: A Canadian retrospective cohort study.
    Rahme E; Godin R; Nedjar H; Dasgupta K; Tagalakis V
    Thromb Res; 2021 Jul; 203():121-130. PubMed ID: 34000493
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease.
    Kimachi M; Furukawa TA; Kimachi K; Goto Y; Fukuma S; Fukuhara S
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011373. PubMed ID: 29105079
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Nazha B; Pandya B; Cohen J; Zhang M; Lopes RD; Garcia DA; Sherwood MW; Spyropoulos AC
    Circulation; 2018 Oct; 138(14):1402-1411. PubMed ID: 29794081
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vitamin-K-antagonist phenprocoumon versus low-dose direct oral anticoagulants (DOACs) in patients with atrial fibrillation: a real-world analysis of German claims data.
    Warkentin L; Hueber S; Deiters B; Klohn F; Kühlein T
    Thromb J; 2022 May; 20(1):31. PubMed ID: 35619140
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of non-adherence to direct oral anticoagulants amongst Swedish patients with non-valvular atrial fibrillation: results from a real-world cost-utility analysis.
    Blomström Lundqvist C; Själander S; Garcia Rodriguez LA; Åkerborg Ö; Jin G; Caleyachetty A; Huelsebeck M; Bowrin K; Schaefer B; Mahdessian H; Hofmeister L; Levin LÅ
    J Med Econ; 2022; 25(1):1085-1091. PubMed ID: 35997241
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of risk factors for inappropriate and suboptimal initiation of direct oral anticoagulants.
    Howard M; Lipshutz A; Roess B; Hawes E; Deyo Z; Burkhart JI; Moll S; Shilliday BB
    J Thromb Thrombolysis; 2017 Feb; 43(2):149-156. PubMed ID: 27757787
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative Effectiveness and Safety of Low-Dose Oral Anticoagulants in Patients With Atrial Fibrillation.
    Perreault S; Dragomir A; Côté R; Lenglet A; de Denus S; Dorais M; White-Guay B; Brophy J; Schnitzer ME; Dubé MP; Tardif JC
    Front Pharmacol; 2021; 12():812018. PubMed ID: 35095525
    [No Abstract]   [Full Text] [Related]  

  • 32. Evaluation of Prescribing Practices and Outcomes Using Direct-acting Oral Anticoagulants After Cardiac Surgery.
    Kanaan DM; Cook BM; Kelly J; Malloy R
    Clin Ther; 2021 Jun; 43(6):e209-e216. PubMed ID: 34078556
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A mixed methodology, non-interventional study to evaluate the use of direct oral anticoagulants in UK clinical practice for patients with a first stroke associated with non-valvular atrial fibrillation: study protocol.
    Bhat Y; Dixit A; Mistri A; Patel B; Quoraishi SH; Uprichard J
    BMC Neurol; 2019 Nov; 19(1):306. PubMed ID: 31783738
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Using primary care data to assess comparative effectiveness and safety of apixaban and rivaroxaban in patients with nonvalvular atrial fibrillation in the UK: an observational cohort study.
    Jaksa A; Gibbs L; Kent S; Rowark S; Duffield S; Sharma M; Kincaid L; Ali AK; Patrick AR; Govil P; Jonsson P; Gatto N
    BMJ Open; 2022 Oct; 12(10):e064662. PubMed ID: 36253039
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of Direct Oral Anticoagulant Prescribing in Patients With Moderate to Severe Renal Impairment.
    Ting C; Rhoten M; Dempsey J; Nichols H; Fanikos J; Ruff CT
    Clin Appl Thromb Hemost; 2021; 27():1076029620987900. PubMed ID: 33517715
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bleeding Risk of Direct Oral Anticoagulants in Patients With Heart Failure And Atrial Fibrillation.
    Jackevicius CA; Lu L; Ghaznavi Z; Warner AL
    Circ Cardiovasc Qual Outcomes; 2021 Feb; 14(2):e007230. PubMed ID: 33541109
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of Prescribing Practices with Direct Acting Oral Anticoagulant Protocols.
    Draper E; Parkhurst B; Carley B; Krueger K; Larson T; Griesbach S
    Am J Cardiovasc Drugs; 2017 Dec; 17(6):475-479. PubMed ID: 28887621
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and effectiveness of appropriately and inappropriately dosed rivaroxaban or apixaban versus warfarin in patients with atrial fibrillation: a cohort study with nested case-control analyses from UK primary care.
    González-Pérez A; Roberts L; Vora P; Saez ME; Brobert G; Fatoba S; García Rodríguez LA
    BMJ Open; 2022 Jun; 12(6):e059311. PubMed ID: 35654463
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists in nonvalvular atrial fibrillation: a Canadian multicentre observational cohort study.
    Durand M; Schnitzer ME; Pang M; Carney G; Eltonsy S; Filion KB; Fisher A; Jun M; Kuo IF; Renoux C; Paterson JM; Quail J; Matteau A;
    CMAJ Open; 2020; 8(4):E877-E886. PubMed ID: 33355273
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Indications for suboptimal low-dose direct oral anticoagulants for non-valvular atrial fibrillation patients.
    Umei M; Kishi M; Sato T; Shindo A; Toyoda M; Yokoyama M; Matsushita M; Ohnishi S; Yamasaki M
    J Arrhythm; 2017 Oct; 33(5):475-482. PubMed ID: 29021853
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.